These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 7559610)
21. Identification and characterization of a novel beta subunit of soluble guanylyl cyclase that is active in the absence of a second subunit and is relatively insensitive to nitric oxide. Nighorn A; Byrnes KA; Morton DB J Biol Chem; 1999 Jan; 274(4):2525-31. PubMed ID: 9891024 [TBL] [Abstract][Full Text] [Related]
22. A variant of the alpha 2 subunit of soluble guanylyl cyclase contains an insert homologous to a region within adenylyl cyclases and functions as a dominant negative protein. Behrends S; Harteneck C; Schultz G; Koesling D J Biol Chem; 1995 Sep; 270(36):21109-13. PubMed ID: 7673142 [TBL] [Abstract][Full Text] [Related]
23. Identification of a novel guanylyl cyclase that is related to receptor guanylyl cyclases, but lacks extracellular and transmembrane domains. Simpson PJ; Nighorn A; Morton DB J Biol Chem; 1999 Feb; 274(7):4440-6. PubMed ID: 9933648 [TBL] [Abstract][Full Text] [Related]
24. Probing the Structural Dynamics of the Catalytic Domain of Human Soluble Guanylate Cyclase. Khalid RR; Maryam A; Sezerman OU; Mylonas E; Siddiqi AR; Kokkinidis M Sci Rep; 2020 Jun; 10(1):9488. PubMed ID: 32528025 [TBL] [Abstract][Full Text] [Related]
26. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. Dependence on glutathione and possible role of S-nitrosation. Mayer B; Schrammel A; Klatt P; Koesling D; Schmidt K J Biol Chem; 1995 Jul; 270(29):17355-60. PubMed ID: 7615539 [TBL] [Abstract][Full Text] [Related]
27. Crystal structures of the catalytic domain of human soluble guanylate cyclase. Allerston CK; von Delft F; Gileadi O PLoS One; 2013; 8(3):e57644. PubMed ID: 23505436 [TBL] [Abstract][Full Text] [Related]
28. Differential expression of functional guanylyl cyclases in melanocytes: absence of nitric-oxide-sensitive isoform in metastatic cells. Ivanova K; Das PK; van den Wijngaard RM; Lenz W; Klockenbring T; Malcharzyk V; Drummer C; Gerzer R J Invest Dermatol; 2001 Mar; 116(3):409-16. PubMed ID: 11231315 [TBL] [Abstract][Full Text] [Related]
29. Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain. Winger JA; Marletta MA Biochemistry; 2005 Mar; 44(10):4083-90. PubMed ID: 15751985 [TBL] [Abstract][Full Text] [Related]
30. Cloning of guanylyl cyclase isoforms. Nakane M; Murad F Adv Pharmacol; 1994; 26():7-18. PubMed ID: 7913620 [TBL] [Abstract][Full Text] [Related]
31. Crystal structure of the signaling helix coiled-coil domain of the beta1 subunit of the soluble guanylyl cyclase. Ma X; Beuve A; van den Akker F BMC Struct Biol; 2010 Jan; 10():2. PubMed ID: 20105301 [TBL] [Abstract][Full Text] [Related]
32. Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site? Lamothe M; Chang FJ; Balashova N; Shirokov R; Beuve A Biochemistry; 2004 Mar; 43(11):3039-48. PubMed ID: 15023055 [TBL] [Abstract][Full Text] [Related]
33. Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation. Johns RA; Tichotsky A; Muro M; Spaeth JP; Le Cras TD; Rengasamy A Anesthesiology; 1995 Oct; 83(4):823-34. PubMed ID: 7574063 [TBL] [Abstract][Full Text] [Related]
35. Identification of sequences mediating guanylyl cyclase dimerization. Wilson EM; Chinkers M Biochemistry; 1995 Apr; 34(14):4696-701. PubMed ID: 7718574 [TBL] [Abstract][Full Text] [Related]
36. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Olesen SP; Drejer J; Axelsson O; Moldt P; Bang L; Nielsen-Kudsk JE; Busse R; Mülsch A Br J Pharmacol; 1998 Jan; 123(2):299-309. PubMed ID: 9489619 [TBL] [Abstract][Full Text] [Related]
37. Conversion of a guanylyl cyclase to an adenylyl cyclase. Beuve A Methods; 1999 Dec; 19(4):545-50. PubMed ID: 10581153 [TBL] [Abstract][Full Text] [Related]
38. The pseudokinase domain in receptor guanylyl cyclases. Bose A; Visweswariah SS Methods Enzymol; 2022; 667():535-574. PubMed ID: 35525553 [TBL] [Abstract][Full Text] [Related]
39. Amino acid substitutions in the Dictyostelium G alpha subunit G alpha 2 produce dominant negative phenotypes and inhibit the activation of adenylyl cyclase, guanylyl cyclase, and phospholipase C. Okaichi K; Cubitt AB; Pitt GS; Firtel RA Mol Biol Cell; 1992 Jul; 3(7):735-47. PubMed ID: 1355376 [TBL] [Abstract][Full Text] [Related]
40. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. Mullershausen F; Russwurm M; Thompson WJ; Liu L; Koesling D; Friebe A J Cell Biol; 2001 Oct; 155(2):271-8. PubMed ID: 11604422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]